Atrial fibrillation and anticoagulation: General practitioner, cardiologist and patient's points of view;Fibrillation atriale et traitement anticoagulant: Point de vue du médecin généraliste, du cardiologue et du patient

Presse Medicale

Volumn 42, Issue 7-8, 2013, Pages

  Liard, François ^a   Le Heuzey, Jean Yves ^b   Aliot, Étienne ^c   Mabo, Philippe ^d   Leenhardt, Antoine ^e  

^a Médecine générale ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CHU NANCY BRABOIS   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K;

ANTICOAGULANT THERAPY; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL STUDY; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ETHNIC GROUP; FRANCE; FRENCH LANGUAGE; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PATIENT COMPLIANCE; PATIENT INFORMATION; PATIENT MONITORING; PRESCRIPTION; PROSPECTIVE STUDY; SELF CONCEPT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; FEMALE; FRANCE; GENERAL PRACTITIONERS; HUMANS; MALE; MIDDLE AGED; PATIENTS; PHYSICIANS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; THROMBOEMBOLISM; VITAMIN K;

EID: 84879411093     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.11.010     Document Type: Article

References (16)

1. Le Heuzey J.Y., Otmani A., Marijon E., Waintraub X., Lepillier A., Chachoua K., et al. Fibrillation atriale: le plus fréquent des troubles du rythme. Presse Med 2008, 37:821-826.
2. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
3. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.
4. Lin H.J., Wolf P.A., Kelly-Hayes M., Beiser A.S., Kase C.S., Benjamin E.J., et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996, 27:1760-1764.
5. Mahé I., Bal dit Sollier C., Duru G., Lamarque H., Bergmann J.F., Drouet L. Utilisation et suivi biologique des antivitamines K en pratique médicale courante. Résultats français de l'étude internationale ISAM chez des patients ayant une fibrillation auriculaire. Presse Med 2006, 35:1797-1803.
6. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
7. Segal J.B., McNamara R.L., Miller M.R., Powe N.R., Goodman S.N., Robinson K.A., et al. Withdrawn: anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev 2007, 3:CD001938.
8. Agence française de sécurité sanitaire des produits de santé. Hémorragies du système nerveux central associées à un traitement AVK: facteurs de risque. Enquête menée avec les Services de neurochirurgie français par l'Association des centres régionaux de pharmacovigilance. http://www.afssaps.fr/Dossiers-thematiques/Anti-vitamine-K-AVK/Etudes-et-enquetes-sur-les-AVK/(offset)/2.
9. Derville J.C. A theory of quota surveys. Survey Methodology 1991, 17:163-181.
10. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., et al. Guidelines for the management of atrial fibrillation. Europace 2010, 12:1360-1420.
11. Aliot E., Breithardt G., Brugada J., Camm J., Lip G.Y., Vardas P.E., et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace 2010, 12:626-633.
12. Mabo P., Leenhardt A., Jaillon P., Kacet S., Aubin F., Denjoy I., et al. Fibrillation atriale, description de la prise en charge par les cardiologues, étude observationnelle. Résultats de l'étude FACTUEL. Ann Cardiol Angeiol 2009, 58:151-158.
13. Zimetbaum P.J., Thosani A., Yu H.T., Xiong Y., Lin J., Kothawala P., et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?. Am J Med 2010, 123:446-453.
14. Peterson G.M., Boom K., Jackson S.L., Vial J.H. Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J 2002, 32:15-23.
15. Poli D., Antonucci E., Testa S., Tosetto A., Ageno W., Palareti G. Italian federation of anticoagulation clinics. Results of a prospective collaborative study on elderly patients followed by Italian centres for anticoagulation. Circulation 2011, 124:824-829.
16. Lip G.Y., Frison L., Halperin J.L., Lane D. Comparative Validation of a Novel Risk Score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011, 57:173-180.